BioMarin Pharmaceutical Sets Its Sights on $2 Billion

BioMarin Pharmaceutical (NASDAQ:BMRN) continued to increase sales of its drugs in the second quarter, adding its seventh commercial product this quarter as it drives toward GAAP profitability. (It's already there on an adjusted basis.)